| Name | Title | Contact Details |
|---|
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
io is a biotechnology company that focuses on improving the quality of protein and overall nutrition through advanced Ingredient Optimized technology. They improve powders and supplements used in food production, transforming the performance of protein...
Headstrong provides cost-free, barrier-free, stigma-free mental health treatment for veterans and their families.
Berkeley Premium Nutraceuticals currently offers six supplements to address issues including sexual health, fatigue, night vision, and cardiovascular health. The Company is also investigating new formulas to assist with other concerns, including prostate
Advanz Pharma Corp. is a multinational pharmaceutical company headquartered in London.